Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HeartSciences (HSCS) Cash from Financing Activities (2022 - 2026)

HeartSciences (HSCS) has disclosed Cash from Financing Activities for 4 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities fell 20.66% year-over-year to $1.5 million, compared with a TTM value of $5.4 million through Oct 2025, down 54.53%, and an annual FY2025 reading of $2.7 million, down 73.57% over the prior year.
  • Cash from Financing Activities was $1.5 million for Q4 2025 at HeartSciences, down from $3.6 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $9.1 million in Q1 2024 and bottomed at -$121522.0 in Q1 2023.
  • Average Cash from Financing Activities over 4 years is $1.7 million, with a median of $667028.5 recorded in 2022.
  • The sharpest move saw Cash from Financing Activities plummeted 106.32% in 2023, then surged 7610.17% in 2024.
  • Year by year, Cash from Financing Activities stood at -$116392.0 in 2022, then skyrocketed by 542.15% to $514629.0 in 2023, then skyrocketed by 269.53% to $1.9 million in 2024, then decreased by 20.66% to $1.5 million in 2025.
  • Business Quant data shows Cash from Financing Activities for HSCS at $1.5 million in Q4 2025, $3.6 million in Q3 2025, and $100028.0 in Q2 2025.